The latest survey from “Business reputation of the pharmaceutical industry” conducted by PatientView located at ViiV Healthcare like the pharmaceutical company with Better company reputation for patients. “We are very happy and proud that patients have chosen us again as they are the most valuable to a pharmaceutical company,” he said MERCA2, the medical director of ViiV Healthcare Spain and Portugal, doctor José E. Martin Herrero.
ViiV Healthcare and PatientView
The top rated company in all categories was ViiV Healthcare, a pharmaceutical company focused on people living with HIV that competes with higher revenue companies in this report. According to the medical director, this is the key to success: “We work by and for people with HIV infection.” innovative medicines and projects to improve their quality of life. “For us, patients always come first.”
The survey conducted by PatientView is already yours ninth version and on this occasion the opinions of 159 Spanish patient associations on the subject were collected Performance of the pharmaceutical industry in 2022.
read 19 pharmaceutical companies evaluated based on the results of the Spanish version The study was selected based on two main criteria: the amount of revenue and the request from the pharmaceutical companies themselves or associations. Finally they were the following: AbbVie, AstraZaneca, Bayer, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, GSK, Janssen, Merck & Co/MSD, Merck KGaA, Novartis, Ostuka, Pfizer, Roche, Sanofi, Takeda and ViiV Healthcare. Furthermore, the 97% of patient associations Participants in 2022 reported working with at least one pharmacist.
Better company reputation
ViiV Healthcare, Gilead Sciences and Novartis are the three pharmaceutical companies involved better reputation of the company for patients in 2022 from a total of 19 companies. In this case, Novartis (+3%), GSK (+2%), Gilead Sciences (+1%) and Sanofi are the pharmaceutical companies that have increased the most in the ranking in Spain in 2022 compared to 2021 (+1% ).
On the other hand, according to them Evaluation of Spanish patient associations who took part in this study and work with the company Ranking Of the top three it is: ViiV Healthcare, Gilead Sciences and Janssen (out of 18 pharmaceutical companies). In this case, the companies that have risen the most In the highest places in 2022 compared to the previous year are: GSK (+6%), ViiV Healthcare (+1%), Novartis (+1%) and Sanofi (+1%).
ViiV Healthcare, Gilead Sciences and Novartis are the three pharmaceutical companies with the best reputation for patients in 2022.
What generally comes out of it Study is that the pharmaceutical industry has been gradually improving its business reputation in Spain since 2018. 59% of patient groups that responded to the 2022 survey believe the pharmaceutical industry’s business reputation is “excellent” or “good” by comparison with 34% as of 2018. On the other hand, 60% of patient associations believe that the pharmaceutical industry is “excellent” or “good” when it comes to innovation, compared to 51% in 2018.
Nevertheless, it still seems necessary to improve since the The industry is low valued in some of its activities. Only 13 percent of the associations surveyed are of the opinion that the pharmaceutical industry is “excellent” or “good” when it comes to establishing a fair pricing policy. Furthermore, only 20% think about it The pricing policy is transparent. Likewise, just 26% said the industry was “excellent” or “good” at improving patient access to medications.
Only 13 percent of the associations surveyed are of the opinion that the pharmaceutical industry is “excellent” or “good” when it comes to establishing a fair pricing policy.
What patients demand from pharmaceutical companies
This scale covers the essential demands of patient associations on companies in the medical industry. Above all, they insist that in Spain they must improve two fundamental aspects: theirs Transparency and access to new medicines for patients.
For example from this Association of patients with cystic fibrosis, is asked to “continue to focus on research that helps expand the circle of people who can benefit from it.” While Spanish Association of Prostate Cancer Patients calls for “to change the current system of approval of new drugs as the EMA approves them, to reduce the cost of new drugs, to force administrations to relax and to speed up the fair process in our country.” “We demand transparency in the entire process,” they conclude.
